1. Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases
   D. Dreymueller et al, 2017, Mediators of Inflammation CrossRef
2. Role of ARPC2 in Human Gastric Cancer.
   Jun Zhang et al, 2017, Mediators Inflamm CrossRef
3. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation.
   Ying Zhao et al, 2017, Oncol Rep CrossRef
4. Secretome within the bone marrow microenvironment: A basis for mesenchymal stem cell treatment and role in cancer dormancy
   Hussam S. Eltoukhy et al, 2018, Biochimie CrossRef
5. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation
   Qi Zhang et al, 2018, Biochemical and Biophysical Research Communications CrossRef
6. Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate
   Rebeca Kawahara et al, 2017, Journal of Proteomics CrossRef
7. Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
   Tobias Meißner et al, 2017, Cold Spring Harb Mol Case Stud CrossRef
8. Effects of ADAM2 silencing on isoflurane-induced cognitive dysfunction via the P13K/Akt signaling pathway in immature rats
   Bao-Juan Zhang et al, 2019, Biomedicine & Pharmacotherapy CrossRef
9. Daphnoretin: An invasion inhibitor and apoptosis accelerator for colon cancer cells by regulating the Akt signal pathway
   Suyang Yu et al, 2019, Biomedicine & Pharmacotherapy CrossRef
10. Structural exploration of arylsulfonamide-based ADAM17 inhibitors through validated comparative multi-QSAR modelling studies
    Sandip Kumar Baidya et al, 2019, Journal of Molecular Structure CrossRef
11. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
    Michael P. Menden et al, 2019, Nat Commun CrossRef
12. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness
    Yuduo Guo et al, 2020, J Neurooncol CrossRef
13. The role of tumor suppressor short non-coding RNAs on breast cancer
    Shokooh Salimimoghadam et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
14. Cyanidin‐3‐ O ‐glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells
    Xu Li et al, 2021, Journal of Food Science CrossRef
15. Expression and purification of a recombinant ELRL-MAP30 with Dual-targeting anti-tumor bioactivity
    Wei-wei Chen et al, 2021, Protein Expression and Purification CrossRef
16. siRNA and targeted delivery systems in breast cancer therapy
    Sepideh Mirzaei et al, 2022, Clin Transl Oncol CrossRef
17. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
    Simon Manuel Tria et al, 2023, Cancers CrossRef
18. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
    Muhammad Tufail et al, 2024, J Transl Med CrossRef
19. ADAM17 promotes colorectal cancer migration and invasion by regulating the TGF-β/Smad signaling pathway
    Jiaming Li et al, 2024, Tissue and Cell CrossRef